May 29- EOD

It seemed like a nice selloff in biotech today. There were the occasional winners (INFI) but for the most part it was a sea of red today. The summer months can be difficult times for biotechs but they have been quite resilient and these sell-offs have ended up being good buying opportunities. 1. I want […]

May 28- Mid Day

This is mid-day instead of the end of the day because I will be out of the office for the rest of the afternoon. This is a little shorter than it should be given the news and moves today but I should have time to add more to this tomorrow. 1. Looks like I have […]

May 24 – End Of Day Biotech Wrap-up

Really another slow day entering into the long weekend. From my perspective, there were really only two really interesting moves. 1. AVEO was a bit of a shocker. AVEO disclosed in a filing that Astellas will no longer fund tivozanib in RCC and would not seek approval in the EU. There are still some other […]

May 23 – End Of Day Biotech Wrap-up

Today was another macro day in that the macro environment had a lot more to do with price movements than fundamentals. That being said, bios seemed to be strong in the morning despite the sell-off and move higher when the market reversed. There was not really a lot of new news today but, as always, […]

May 22 – End Of Day Biotech Wrap-up

While the market got some intraday whipsaw action, it seemed generally good and biotechs did well- early. We had a late day sell-off with biotechs seeming to do better than the market in general. 1. It seems like just yesterday I was positive but cautious on ARIA because it was still making lower high and […]

May 21 – End Of Day Biotech Wrap-up

Perhaps it is the start of the summer season but the market seems to have been quite the past couple of days or perhaps I am simply looking at the wrong parts of the market. 1. There were a number of EHA abstracts released today for PCYC and perhaps one of the most important was […]

May 20th – End Of Day Biotech Wrap-up

Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak but not in a significant manner. Perhaps we are having the quite before the storm. 1. PPHM announced its agreement with the FDA on a […]